Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder

Overview

Journal Drugs

Specialty Pharmacology

Date 2019 Aug 31

PMID 31468317

Citations 7

Authors

Jean-Michel Azorin

Nicolas Simon

Affiliations

Soon will be listed here.

Abstract

Bipolar disorder is a chronic, disabling, and costly illness with frequent relapses and recurrences, high rates of co-morbid conditions, and poor adherence to treatment. Mood stabilizers and antipsychotics are the cornerstones of treatment. Dopamine receptor partial agonists are a novel class of antipsychotic agents with original pharmacodynamic properties. Among them, two have been approved by the US Food and Drug Administration for the treatment of bipolar disorder. Aripiprazole (oral formulation) has been approved as monotherapy for the treatment of manic/mixed episodes in adult and pediatric populations and for maintenance treatment in adults, and as adjunctive treatment to mood stabilizers, for the acute treatment of manic/mixed episodes and for maintenance in adults. An intramuscular formulation of aripiprazole has been approved for the treatment of agitation in mania and a long-acting injectable formulation has been approved as maintenance treatment. In the USA, cariprazine has been approved as monotherapy for the acute treatment of manic/mixed as well as bipolar depressive episodes. Brexpiprazole is not yet approved to treat bipolar disorder. The evidence supporting these indications is reviewed via an analysis of clinical registration trials as well as additional studies, on the basis of a systematic literature search. Further studies dealing with other aspects of bipolar illness are also presented. Aripiprazole and cariprazine are efficacious and generally well tolerated agents that have shown cost effectiveness, and may therefore enrich our therapeutic armamentarium for bipolar illness. Brexpiprazole, which displays an overall promising tolerability profile, deserves further efficacy studies.

Citing Articles

The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors.

Hardy R, Chung I, Yu Y, Loh S, Morone N, Soleilhavoup C Biol Direct. 2023; 18(1):43.

PMID: 37528429 PMC: 10391878. DOI: 10.1186/s13062-023-00375-9.

Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy.

Ferreira M, Duarte J, Veiga F, Paiva-Santos A, Pires P Pharmaceutics. 2023; 15(2).

PMID: 36840000 PMC: 9959474. DOI: 10.3390/pharmaceutics15020678.

Dopamine, Immunity, and Disease.

Channer B, Matt S, Nickoloff-Bybel E, Pappa V, Agarwal Y, Wickman J Pharmacol Rev. 2023; 75(1):62-158.

PMID: 36757901 PMC: 9832385. DOI: 10.1124/pharmrev.122.000618.

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Tsermpini E, Redensek S, Dolzan V Front Pharmacol. 2022; 12:834129.

PMID: 35140610 PMC: 8819690. DOI: 10.3389/fphar.2021.834129.

Computational study on new natural compound agonists of dopamine receptor.

Li H, Yang W, Xi J, Wang Z, Lu H, Du Z Aging (Albany NY). 2021; 13(12):16620-16636.

PMID: 34170848 PMC: 8266345. DOI: 10.18632/aging.203180.

References

Merikangas K, Akiskal H, Angst J, Greenberg P, Hirschfeld R, Petukhova M . Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007; 64(5):543-52. PMC: 1931566. DOI: 10.1001/archpsyc.64.5.543. View

Sachs G, Greenberg W, Starace A, Lu K, Ruth A, Laszlovszky I . Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2014; 174:296-302. DOI: 10.1016/j.jad.2014.11.018. View

Tramontina S, Zeni C, Ketzer C, Pheula G, Narvaez J, Rohde L . Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009; 70(5):756-64. DOI: 10.4088/JCP.08m04726. View

Calabrese J, Jin N, Johnson B, Such P, Baker R, Madera J . Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. Int J Bipolar Disord. 2018; 6(1):14. PMC: 6162003. DOI: 10.1186/s40345-018-0122-z. View

Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W . Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006; 20(4):536-46. DOI: 10.1177/0269881106059693. View

Thase M, Bowden C, Nashat M, Eudicone J, Marcus R, McQuade R . Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms. Int J Psychiatry Clin Pract. 2012; 16(2):121-31. DOI: 10.3109/13651501.2011.632680. View

Earley W, Durgam S, Lu K, Ruth A, Nemeth G, Laszlovszky I . Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. 2017; 226:239-244. DOI: 10.1016/j.jad.2017.09.040. View

Calabrese J, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B . Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study. J Clin Psychiatry. 2017; 78(3):324-331. DOI: 10.4088/JCP.16m11201. View

Das S, Barnwal P, Winston A B, Mondal S, Saha I . Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016; 6(1):39-54. PMC: 4749739. DOI: 10.1177/2045125315614739. View

10.

Howland R . Brexpiprazole: another multipurpose antipsychotic drug?. J Psychosoc Nurs Ment Health Serv. 2015; 53(4):23-5. DOI: 10.3928/02793695-20150323-01. View

11.

Grunder G . Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs. 2010; 11(7):823-32. View

12.

Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J . Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2013; 171(2):169-77. DOI: 10.1176/appi.ajp.2013.13070985. View

13.

Lee L, Choi C, Collier A, Barr A, Honer W, Procyshyn R . The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values. CNS Drugs. 2015; 29(12):975-83. DOI: 10.1007/s40263-015-0295-2. View

14.

Muneer A . The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Cureus. 2016; 8(4):e562. PMC: 4859817. DOI: 10.7759/cureus.562. View

15.

Li X, Jope R . Is glycogen synthase kinase-3 a central modulator in mood regulation?. Neuropsychopharmacology. 2010; 35(11):2143-54. PMC: 3055312. DOI: 10.1038/npp.2010.105. View

16.

Thase M, Jonas A, Khan A, Bowden C, Wu X, McQuade R . Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008; 28(1):13-20. DOI: 10.1097/jcp.0b013e3181618eb4. View

17.

Perlis R, Welge J, Vornik L, Hirschfeld R, Keck Jr P . Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006; 67(4):509-16. DOI: 10.4088/jcp.v67n0401. View

18.

Crump C, Sundquist K, Winkleby M, Sundquist J . Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013; 70(9):931-9. DOI: 10.1001/jamapsychiatry.2013.1394. View

19.

Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S . Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials. Eur Neuropsychopharmacol. 2015; 25(11):1882-91. DOI: 10.1016/j.euroneuro.2015.08.020. View

20.

Urs N, Gee S, Pack T, McCorvy J, Evron T, Snyder J . Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci U S A. 2016; 113(50):E8178-E8186. PMC: 5167191. DOI: 10.1073/pnas.1614347113. View